XP-828L in the Treatment of Mild-to-Moderate Psoriasis: A ...

More documents

Recommendations

Info

Original ResearchAlternative Medicine Review Volume 12, Number 4 2007not complete the entire study. Five patients discontinuedfollowing consent withdrawal, two patientsbecause of unrelated adverse events, and two patientsdiscontinued owing to disease progression.Compliance with the test product was 93% in bothgroups. The per protocol data set excluded six patientsfor whom compliance with testing the productwas less than 80%.Treatment EfficacyA clinical improvement in the psoriasisplaque severity was associated with a decrease inPGA, PASI, BSA, and the severity of the itch.Physician’s Global Assessment: IntergroupAnalysisIn the intent-to-treat data set, the PGAscore at day 56 was lower in XP-828L-treated patientsthan in the placebo group (p
Alternative Medicine Review Volume 12, Number 4 2007Psoriasis StudyPsoriasis Area and Severity Index: IntragroupAnalysisIn the intent-to-treat data set of group A, thePASI score decreased from 8.94 ± 3.97 at day 1 to 8.36± 4.31 at day 56 (p
Page 1: OriginalResearchAlternative Medicin
Page 6 and 7: Original ResearchAlternative Medici
Page 8: Original ResearchAlternative Medici

XP-828L in the Treatment of Mild-to-Moderate Psoriasis: A ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?